Marcin Siwek1, Magdalena Sowa-Kućma2, Krzysztof Styczeń1, Bernadeta Szewczyk2, Witold Reczyński3, Paulina Misztak4, Roman Topór-Mądry5, Gabriel Nowak4, Dominika Dudek1, Janusz K Rybakowski6. 1. Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Krakow, Poland. 2. Laboratory of Trace Elements Neurobiology, Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland. 3. Chair of Analytical Chemistry, University of Science and Technology, Krakow, Poland. 4. Laboratory of Trace Elements Neurobiology, Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland; Chair of Pharmacobiology, Jagiellonian University Medical College, Krakow, Poland. 5. Department of Epidemiology and Population Studies, Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland. 6. Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland. Electronic address: janusz.rybakowski@gmail.com.
Abstract
OBJECTIVES: Zinc may be involved in the pathophysiology and treatment of depressive disorder. However, data on this issue in bipolar disorder (BD) are limited. The aim of the study was to assess zinc concentrations in the blood serum of patients at various phases and stages of bipolar disorder. METHODS: The study included 129 patients with a diagnosis of bipolar disorder type I (n=69) or type II (n=60). Fifty-eight were in a depressive episode, 23 in a manic episode and 48 in remission. Fifty healthy volunteers made a control group. Zinc concentration was measured using flame atomic absorption spectrometry. RESULTS: Serum zinc level in patients diagnosed with BD type I in the depressive phase was significantly reduced as compared with mania, remission and healthy subjects. In the BD type II, serum zinc level in hypomania, depression or remission phase was not significantly different from the control group. In the whole group, lower level of zinc in depression compared to remission and control subjects was found during late stage of the illness but not in the early stage. Zinc concentration was not dependent on the severity of manic or depressive symptoms and subtype of depression but correlated positively with the number of manic/hypomanic relapses in the past year. LIMITATIONS: Lack of prospective model, heterogeneity of pharmacological treatment, small number of subgroups presenting specified clinical features. CONCLUSIONS: Decreased serum zinc concentration occurs in depression in BD type I and probably in depression in the late stage of BD.
OBJECTIVES: Zinc may be involved in the pathophysiology and treatment of depressive disorder. However, data on this issue in bipolar disorder (BD) are limited. The aim of the study was to assess zinc concentrations in the blood serum of patients at various phases and stages of bipolar disorder. METHODS: The study included 129 patients with a diagnosis of bipolar disorder type I (n=69) or type II (n=60). Fifty-eight were in a depressive episode, 23 in a manic episode and 48 in remission. Fifty healthy volunteers made a control group. Zinc concentration was measured using flame atomic absorption spectrometry. RESULTS: Serum zinc level in patients diagnosed with BD type I in the depressive phase was significantly reduced as compared with mania, remission and healthy subjects. In the BD type II, serum zinc level in hypomania, depression or remission phase was not significantly different from the control group. In the whole group, lower level of zinc in depression compared to remission and control subjects was found during late stage of the illness but not in the early stage. Zinc concentration was not dependent on the severity of manic or depressive symptoms and subtype of depression but correlated positively with the number of manic/hypomanic relapses in the past year. LIMITATIONS: Lack of prospective model, heterogeneity of pharmacological treatment, small number of subgroups presenting specified clinical features. CONCLUSIONS: Decreased serum zinc concentration occurs in depression in BD type I and probably in depression in the late stage of BD.
Authors: Grzegorz Satała; Beata Duszyńska; Tomasz Lenda; Gabriel Nowak; Andrzej J Bojarski Journal: Mol Neurobiol Date: 2017-04-28 Impact factor: 5.590
Authors: Bo H Jonsson; Funda Orhan; Sanna Bruno; Ana Osório Oliveira; Timea Sparding; Mikael Landen; Carl M Sellgren Journal: Brain Behav Date: 2021-12-30 Impact factor: 2.708